Providing services for the earlier detection of disease through proprietary machine learning and digital pathology infrastructure.
Developed by Cyted, the Cytosponge®-TFF3 is a novel, inexpensive non-invasive diagnostic test for Barrett’s Oesophagus that could revolutionise the clinical care pathway. The aim is to systematically use a positive Cytosponge test to identify patients at-risk of early oesophageal cancer and so prioritise for endoscopic confirmation and treatment.
The Cytosponge technology has been developed and supported by scientists at the University of Cambridge from conception, through clinical studies, to the ongoing implementation pilot. The oesophageal cell sample is transported to the Cyted laboratory for processing and analysis. The proprietary digital pathology infrastructure and artificial intelligence technology increase the ease and throughput of screening, enabling consultant pathologists to focus on more difficult cases.
If you'd like to discuss this Innovation, have an idea or a new Innovation, please get in touch.